Figure 5

a) Viability (MTT-uptake) for unstimulated and stimulated cells with ERK1/2-I, p38-I, and JNK-I.

b) Relative amount of IL-1β mRNA in LPS-treated cells with ERK1/2-I, p38-I, and JNK-I.

c) CSN1S1 mean fluorescence intensity in CD14 and CD64.

d) CSN1S1 mean fluorescence intensity in CD14 under the influence of M-CSF.

e) GM-CSF mean fluorescence intensity in CD14 and CD64.

f) IL-6 production in control and CSN1S1-treated cells with ERK-I, p38-I, and JNK-I.

g) IL-1β production in control and CSN1S1-treated cells with ERK-I, p38-I, and JNK-I.

h) Phosphorylation status of p38, JNK, and ERK with CSN1S1 treatment.